Table 1.

General and clinical characteristics of patients and controls

	NDMM (n = 36)	SMM (n = 11)	MGUS (n = 24)	Controls (n = 26)
Age, median (range), y	69 (38-90)	73 (50-85)	64 (42-89)	60 (35-84)
Sex, male, n (%)	20 (55)	5 (45)	7 (29)	12 (46)
ISS stage,* n (%)
ISS1	11 (34)	3 (37.5)	NA	NA
ISS2	10 (32)	3 (37.5)	NA	NA
ISS3	11 (36)	2 (25)	NA	NA
Isotype, n (%)
IgG	21 (60)	NA	NA	NA
IgA	8 (23)	NA	NA	NA
Light chain	6 (17)	NA	NA	NA
Oligosecretory	1 (3)	NA	NA	NA
Cytogenetics, n (%)	33 (92)	NA	NA	NA
17p deletion	4 (12)	NA	NA	NA
−1p and/or +1q	13 (40)	NA	NA	NA
FISH,† n (%)	20 (55)	NA	NA	NA
t(4;14)	2 (11)	NA	NA	NA
t(14;16)	0 (0)	NA	NA	NA
LDH,‡ median (range), U/L	157 (89-407)	NA	NA	NA
Above normal, n (%)	5 (18)	NA	NA	NA

FISH, fluorescence in situ hybridization; IgA, immunoglobulin A; IgG, immunoglobulin G; ISS, International Staging System; LDH, lactate dehydrogenase; NA, not available.

^*β2 microglobulin available for ISS grading in 32 out of 36 NDMM patients and 8 out of 11 SMM patients.

^†High-risk genetics by FISH, including del17p, t(4;14), and t(14;16), were tested in 20 out of 36 NDMM patients.

^‡Available in 28 out of 36 NDMM patients.